NKTX News and Press, Nkarta Inc.

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8 th Annual Healthcar...

2025-11-22 08:28:11 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason

2025-11-10 16:52:13 ET Nkarta press release ( NKTX ): Q3 GAAP EPS of -$0.29 beats by $0.02 . Nkarta had cash, cash equivalents, restricted cash, and investments in marketable securities of $316.5 million as of September 30, 2025. Research and development (R&D) ...

Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamide Enrol...

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 He...

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the...

2025-10-17 07:01:47 ET Shares of autoimmune and oncology concern Cullinan Therapeutics, Inc. ( CGEM ) are down approximately 70% since May 2024, owing to a data vacuum from its off-the-shelf CD19xCD3 T cell engager CLN-978. The now autoimmune therapy should provide eagerly await...

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 27 ...

2025-08-12 16:51:51 ET More on Nkarta Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025 Seeking Alpha’s Quant Rating on Nkarta Historical earnings data for Nkarta Financial information for Nkarta Read the full article on...